Background/aim: Metastatic anaplastic thyroid cancer is associated with a dismal prognosis. We evaluated outcome and prognostic factors in patients receiving radiation to the primary tumor in metastatic anaplastic thyroid cancer (ATC).
Patients And Methods: All consecutive patients with metastatic ATC (n=20) undergoing irradiation between 2009 and 2019 for anaplastic thyroid cancer were investigated.
Results: Median survival time and median progression-free survival were 2 (range=1-22) and 2 (1-20) months. In univariate analyses, surgery, concurrent or sequential chemotherapy and higher radiation dose escalation (>39 Gy) were correlated with longer overall survival (p=0.005, p=0.018 and p=0.038), respectively. Karnofsky performance status >70% showed a trend of longer survival time (p=0.062). Limited metastatic disease, surgery and concurrent/sequential chemotherapy are correlated with longer progression-free survival times (p=0.043, p=0.024 and p=0.039), respectively.
Conclusion: Radiation to the primary tumor in metastatic anaplastic thyroid cancer is safe and offers durable local control. Treatment intensification including concurrent or sequential chemotherapy and radiation dose escalation were associated with longer survival rates and should be considered in selected patients with metastatic disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880735 | PMC |
| http://dx.doi.org/10.21873/invivo.12279 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine learning-based prognostic model for patients with anaplastic thyroid carcinoma.
Discov Oncol
January 2025
Department of Thyroid Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Objective: Despite the identification of various prognostic factors for anaplastic thyroid carcinoma (ATC) patients over the years, a precise prognostic tool for these patients is still lacking. This study aimed to develop and validate a prognostic model for predicting survival outcomes for ATC patients using random survival forests (RSF), a machine learning algorithm.
Methods: A total of 1222 ATC patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and randomly divided into a training set of 855 patients and a validation set of 367 patients.
Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
Oral Oncol
January 2025
School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China; Department of Otolaryngology Head and Neck Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing 210019, Jiangsu, China. Electronic address:
Thyroid cancer progression from curable well-differentiated thyroid carcinoma to highly lethal anaplastic thyroid carcinoma is distinguished by tumor cell de-differentiation and recruitment of a robust stromal infiltrate. Combining an integrated thyroid cancer single-cell sequencing atlas with spatial transcriptomics and bulk RNA-sequencing, we define stromal cell subpopulations and tumor-stromal cross-talk occurring across the histologic and mutational spectrum of thyroid cancer. We identify distinct inflammatory and myofibroblastic cancer-associated fibroblast (iCAF and myCAF) populations and perivascular-like populations.
View Article and Find Full Text PDFMetastatic Anaplastic Thyroid Carcinoma to the Right Ventricle.
JACC Case Rep
December 2024
Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Anaplastic thyroid carcinoma (ATC) is a rare, yet extremely aggressive form of thyroid cancer characterized by rapid growth and early metastasis to distant sites. Cardiac involvement is very uncommon and the presentation of cardiac metastasis in ATC can vary widely, highlighting the importance of early clinical recognition. We describe an extremely rare case of metastatic ATC that spread to the right ventricle.
View Article and Find Full Text PDFMorphine-Induced Elevation of Reactive Oxygen Species Attenuates Chemotherapy Efficacy in Diverse Cancer Cell Types.
Curr Mol Med
January 2025
Department of Anesthesiology, Baoan Central Hospital of Shenzhen, Shenzhen, Guangdong Province, China.
Background: Morphine, a mu-opioid receptor (MOR) agonist commonly utilized in clinical settings alongside chemotherapy to manage chronic pain in cancer patients, has exhibited contradictory effects on cancer, displaying specificity toward certain cancer types and doses.
Objective: The aim of this study was to conduct a systematic assessment and comparison of the impacts of morphine on three distinct cancer models in a preclinical setting.
Methods: Viability and apoptosis assays were conducted on a panel of cancer cell lines following treatment with morphine, chemotherapy drugs alone, or their combination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!